Sensinnovat

Total investments

3

Average round size

19M

Portfolio companies

2

Follow on index

0.33

Areas of investment
Health CareManufacturingMedical DeviceMedicalNanotechnologyDiabetes

Summary

Among the most popular portfolio startups of the fund, we may highlight Indigo Diabetes. We can highlight the next thriving fund investment areas, such as Medical Device, Diabetes.

The standard case for the fund is to invest in rounds with 9 partakers. The meaningful sponsors for the fund in investment in the same round are Thuja Capital, SoFi, Qbic Fund.

The fund is constantly included in less than 2 investment rounds annually. Deals in the range of 5 - 10 millions dollars are the general things for fund. The important activity for fund was in 2016.

Show more

Investments analytics

Analytics

Total investments
3
Lead investments
0
Follow on index
0.33
Investments by industry
  • Diabetes (2)
  • Health Care (2)
  • Medical Device (2)
  • Medical (2)
  • Manufacturing (1)
  • Show 1 more
Investments by region
  • Belgium (2)
  • France (1)
Peak activity year
2022

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
4
Group Appearance index
1.00

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Hummink 15 Nov 2022 Manufacturing, Nanotechnology Seed 5M Ile-de-France, Paris, France
How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.